Engineering Oncolytic Adenoviruses with VSVG‐Decorated Tumor Cell Membranes for Synergistically Enhanced Antitumor Therapy

Oncolytic viruses hold great promise for cancer treatment but their practical applications are seriously impaired by a series of limitations. Herein, an engineered oncolytic adenovirus (OA) is constructed that can boost both the direct oncolysis and antitumor immune response of OA attributed to the...

Full description

Saved in:
Bibliographic Details
Published in:Advanced functional materials 2023-01, Vol.33 (3), p.n/a
Main Authors: Huang, Li‐Li, Wang, Weiwei, Wang, Zhongjie, Zhang, Han, Liu, Houli, Wu, Guanghao, Nie, Weidong, Xie, Hai‐Yan
Format: Article
Language:English
Subjects:
Adenoviruses
Antigens
Cell membranes
Glycoproteins
Immune system
immunotherapy
low‐pH activated membrane fusions
Materials science
oncolytic adenoviruses
Side effects
tumor cell membranes
vesicular stomatitis virus glycoprotein
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oncolytic viruses hold great promise for cancer treatment but their practical applications are seriously impaired by a series of limitations. Herein, an engineered oncolytic adenovirus (OA) is constructed that can boost both the direct oncolysis and antitumor immune response of OA attributed to the increased tumor targeting and low‐pH responsive fusogenic activity. The tumor cell membranes are decorated with vesicular stomatitis virus glycoprotein (VSVG) via vesicular stomatitis virus (VSV) infection and then used to mask OA (V‐M@OA). After systemic administration, the engineered OA can target homologous tumors owing to the homing ability of tumor membranes. Then the unique low‐pH responsive fusogenic activity of VSVG significantly enhances the replication of OA by promoting the whole virus infection process, resulting in remarkable virus‐mediated tumoricidal effects and thus abundant in situ released tumor‐associated antigens (TAAs). Meanwhile, VSVG on V‐M@OA augments the adjuvanticity of OA and thus significantly enhancing the antitumor immune response. The synergism of virus‐mediated killing and immune effects leads to significant tumor inhibition with no obvious side effects. An engineered oncolytic adenovirus (OA) is constructed by coating OA with vesicular stomatitis virus glycoprotein‐decorated tumor cell membranes. The obtained V‐M@OA can overcome the series of limitations of OA‐based tumor therapy, enhancing both the direct oncolysis and antitumor immunology. It provides a novel idea to put forward the universal application of OA in oncolytic virotherapies.
ISSN:1616-301X
1616-3028
DOI:10.1002/adfm.202209056